Company performance
Add to research
Current Price
as of Jun 11, 2025$1.55
P/E Ratio
N/A
Market Cap
$177.68M
Description
Add to research
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerFATE
- Price$1.55-7.19%
Trading Information
- Market cap$177.68M
- Float93.42%
- Average Daily Volume (1m)2,035,733
- Average Daily Volume (3m)2,030,418
- EPS-$1.49
Company
- Revenue$13.34M
- Rev growth (1yr)-15.38%
- Net income-$37.62M
- Gross margin-104.60%
- EBITDA margin-2,329.47%
- EBITDA-$37.95M
- EV-$63.56M
- EV/Revenue-4.77
- P/EN/A
- P/S13.76
- P/B0.62
- Debt/Equity28.89
Documents
Add to research
SEC Filings
Earnings Calls